Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

Chung Hoow Kok(South Australian Health and Medical Research Institute), Timothy P. Hughes(South Australia Pathology), Deborah L. White(ANZCHOG), John Reynolds(Deakin University), Verity A Saunders(South Australia Pathology), Lu Liu(South Australian Health and Medical Research Institute), Tamara Leclercq(South Australian Health and Medical Research Institute), David T Yeung(South Australia Pathology), Phuong Dang(South Australia Pathology), Dale B. Watkins(South Australian Health and Medical Research Institute)
Blood Advances
May 24, 2019
10.1182/bloodadvances.2019000195
Cited by 43

Related Papers

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
|Blood|2013|705
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
|Leukemia|2012|440
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
|Leukemia|2012|417